Biomedical Industry Enters Innovation 3.0 Era,Guotai CSI BIOMEDICINE ETF (512290) Pulls Back 1.40%

NewTimeSpace News – As of 14:19 on January 19, 2026, Biomedical ETF (512290) fell 1.40%, with the latest price at RMB 1.06. Looking at a longer timeframe, as of January 16, 2026, the ETF has accumulated a 7.10% gain over the past two weeks. (The stocks listed above are index constituents only and do not constitute specific investment recommendations.)

In terms of liquidity, Biomedical ETF recorded an intraday turnover ratio of 2.44% with trading volume of RMB 83.9450 million. Over a broader period, as of January 16, the ETF's average daily trading volume over the past week reached RMB 99.3551 million.

Regarding scale, Biomedical ETF's latest assets under management reached RMB 3.465 billion. (Data source: Wind)

In terms of fund flows, Biomedical ETF recorded latest net capital inflow of RMB 1.0747 million. Looking at a longer period, 10 out of the past 19 trading days saw capital inflows, totaling RMB 53.2971 million in "capital attraction" with an average daily net inflow of RMB 2.8051 million. (Data source: Wind)

Data shows leveraged funds continue to build positions. Biomedical ETF's latest margin purchase reached RMB 6.7195 million, with the latest financing balance at RMB 135 million. (Data source: Wind)

As of January 16, Biomedical ETF's NAV has increased 24.49% over the past year.

In terms of return capability, as of January 16, 2026, since its inception, the ETF's highest monthly return reached 23.26%, the longest consecutive gain period lasted 8 months with a total gain of 109.28%, and the average return during positive months was 6.70%. As of January 16, 2026, Biomedical ETF's annualized excess return over benchmark since inception is 2.64%.

As of January 16, 2026, Biomedical ETF's Sharpe ratio over the past year stands at 1.24.

Regarding drawdown, as of January 16, 2026, Biomedical ETF's maximum year-to-date drawdown was 2.93%, with a relative benchmark drawdown of 0.02%.

In terms of fees, Biomedical ETF's management fee rate is 0.50% and custody fee rate is 0.10%.

In tracking accuracy, as of January 16, 2026, Biomedical ETF's year-to-date tracking error was 0.004%.

Biomedical ETF closely tracks the CSI Biomedical Index. The CSI Biomedical Index selects listed securities of companies providing products and services such as cell therapy, gene sequencing, blood products, biotechnology drugs, vaccines, and in vitro diagnostics as index constituents to reflect the overall performance of biomedical listed companies.

Industrial Securities stated that the biomedical industry has entered the Innovation 3.0 era. China's innovative drugs have shown a leading trend in new targets, new technologies, and new disease areas, particularly holding competitive advantages in hot technology tracks such as ADC, bispecific antibodies, and small nucleic acids. The domestic CRO prosperity inflection point is clear, with orders showing a trend of rising volume and price since 2025, benefiting from innovative drug BD overseas and financing stabilization and recovery, with multiple CRO companies' new order signings accelerating quarter by quarter.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.